Pediatric anesthesia & critical care
Pharmacokinetics and Pharmacodynamics of Remimazolam for Procedural Sedation in Children and Adolescents
Authors' conclusion
This study has shown that the pharmacokinetics of remimazolam are likely different between children 6 yr or older and adults (after correcting for size).
Study context
- Population
- Pediatric patients aged 6 to 18 yr receiving remimazolam for procedural sedation
- Participants
- 31 patients
- Comparison
- Remimazolam bolus vs infusion, each with or without fentanyl
- Outcome
- PK and PD of remimazolam
Methodological detailsfour treatment arms, model-based dose optimisation, simulations
- Four treatment arms
- Model-based dose optimisation
- Simulations
Main finding
As reported in the abstract
- Elimination clearance of remimazolam
- 0.70 l · min −1 · 70 kg −1
- EC50 of remimazolam for UMSS ≥3, no fentanyl
- 777 ng · ml −1
- EC50 for UMSS ≥3 with fentanyl steady state 1 ng · ml −1
- 655 ng/ml
- EC50 for UMSS ≥3 with fentanyl steady state 2 ng · ml −1
- 533 ng/ml
- EC50 for UMSS ≥3 with fentanyl steady state 4 ng · ml −1
- 287 ng/ml
Further findings
Simulated patients not reaching UMSS ≥3 at end of induction, studied regimen
- Patients not reaching UMSS ≥3
- 9.2 to 22.0%
- Simulations
Simulated patients achieving UMSS ≥3, optimised regimen (higher per-kg doses, no maximum dose)
- Patients achieving UMSS ≥3
- 88 to 97%
- Simulations
Original publication
Pharmacokinetics and Pharmacodynamics of Remimazolam for Procedural Sedation in Children and Adolescents. Anesthesiology. Published 12 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →